The ALSFRS-R Summit: a global call to action on the use of the ALSFRS-R in ALS clinical trials.
Clinical trial design
clinical trial outcome measures
functional rating scale
harmonization
statistical analysis
Journal
Amyotrophic lateral sclerosis & frontotemporal degeneration
ISSN: 2167-9223
Titre abrégé: Amyotroph Lateral Scler Frontotemporal Degener
Pays: England
ID NLM: 101587185
Informations de publication
Date de publication:
23 Feb 2024
23 Feb 2024
Historique:
medline:
24
2
2024
pubmed:
24
2
2024
entrez:
24
2
2024
Statut:
aheadofprint
Résumé
The Amyotrophic Lateral Sclerosis Functional Rating Scale (ALSFRS) was developed more than 25 years ago as an instrument to monitor functional change over time in patients with ALS. It has since been revised and extended to meet the needs of high data quality in ALS trials (ALSFRS-R), however a full re-validation of the scale was not completed. Despite this, the scale has remained a primary outcome measure in clinical trials. We convened a group of clinical trialists to discuss and explore opportunities to improve the scale and propose alternative measures. In this meeting report, we present a call to action on the use of the ALSFRS-Revised scale in clinical trials, focusing on the need for (1) harmonization of the ALSFRS-R administration globally, (2) alignment on a set of recommendations for clinical trial design and statistical analysis plans (SAPs), and (3) use of additional outcome measures.
Identifiants
pubmed: 38396337
doi: 10.1080/21678421.2024.2320880
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM